Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 48

Results For "safety"

1230 News Found

USFDA grants priority review for Patritumab Deruxtecan in US for certain patients with EGFR-mutated non-small cell lung cancer
Drug Approval | December 23, 2023

USFDA grants priority review for Patritumab Deruxtecan in US for certain patients with EGFR-mutated non-small cell lung cancer

If approved, patritumab deruxtecan would be a first-in-class HER3 directed DXd antibody drug conjugate for these patients


Lupin launches liquid fibre Softovac Liquifibre
News | December 22, 2023

Lupin launches liquid fibre Softovac Liquifibre

Softovac Liquifibre expands the Softovac product portfolio and provides a choice for consumers who prefer time-tested Ayurvedic ingredients


Asahi Kasei opens new Bioprocess Technical Center in China
News | December 20, 2023

Asahi Kasei opens new Bioprocess Technical Center in China

The bioprocess business will continue to pioneer contributions to safety and productivity in the manufacture of biotherapeutics


FDA grants priority review to Merck’s new biologics license application for V116
Drug Approval | December 20, 2023

FDA grants priority review to Merck’s new biologics license application for V116

V116 is an investigational, 21-valent pneumococcal conjugate vaccine specifically designed to protect adults


Zydus receives USFDA approval USFDA to initiate Phase II clinical trial of ZYIL1 for Parkinson's disease
Drug Approval | December 18, 2023

Zydus receives USFDA approval USFDA to initiate Phase II clinical trial of ZYIL1 for Parkinson's disease

Studies have demonstrated that ZYIL1 is highly potent and can suppress inflammation caused by NLRP3 inflammasome activation


TÜV SÜD inaugurates € 15 million Laboratory & Training Centre Bengaluru Campus
News | December 17, 2023

TÜV SÜD inaugurates € 15 million Laboratory & Training Centre Bengaluru Campus

Expansion of presence in India with electrical safety, electromagnetic compatibility and medical device biocompatibility, toxicity and microbiology testing and certification services


Pfizer presents marstacimab Phase 3 Data at ASH 2023
News | December 10, 2023

Pfizer presents marstacimab Phase 3 Data at ASH 2023

Demonstrate significant bleed reduction in hemophilia A and B


European Commission approves Pfizer’s Elrexfio for multiple myeloma
Drug Approval | December 09, 2023

European Commission approves Pfizer’s Elrexfio for multiple myeloma

Conditional marketing authorization is based on clinically meaningful response rates, duration of response, and safety from the Phase 2 MagnetisMM-3 trial


Operations disrupted at NATCO Pharma's Manali, Chennai factory
News | December 08, 2023

Operations disrupted at NATCO Pharma's Manali, Chennai factory

NATCO temporarily shut down the operations due to cyclone with flooding/water logging of the factory premises


Sarclisa Phase 3 trial met primary endpoint of progression free survival with newly diagnosed multiple myeloma not eligible for transplant
News | December 08, 2023

Sarclisa Phase 3 trial met primary endpoint of progression free survival with newly diagnosed multiple myeloma not eligible for transplant

Sarclisa added to bortezomib, lenalidomide and dexamethasone (VRd) significantly reduced the risk of disease progression or death compared with VRd alone